Actually not the update. 9/18 was a listening circle to discuss where cyclodextrins fit in the proposed treatment options for NPC and how it mediates its benefits in the disease.
The update is 9/19. CTDH will give a formal presentation on progress in its clinical trials program. See below.
CTD Holdings to Present at UK Annual Conference for NPC Patients, Families and Caregivers
Gathering Provides Opportunity to Discuss Progress of CTD's International Clinical Program
ALACHUA, FL -- (Marketwired) -- 09/03/15 -- September 3, 2015 - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, will make a formal presentation on progress in its clinical trials program on September 19 at a major annual meeting of caregivers and families struggling with Niemann-Pick Type C (NPC) disease. The meeting will be convened in Bedfordshire, England, under the auspices of the Niemann-Pick UK, a registered charity in the United Kingdom. The annual meeting brings together experts from around the world for interactive sessions on clinical and practical management of NPC, and on clinical trials aimed at slowing the progression of the disease. The company's formal presentation will be held on Saturday, September 19.
"We look forward to sharing information on our company's history in meeting the needs of NPC families globally with Trappsol® Cyclo™, and having opportunities to interact directly with those most impacted by NPC," said Executive Chairman N. Scott Fine.
"We welcome discussions with families and health professionals about our international clinical program progress, and we are eager to work with NP-UK in hosting our Family and Physician Listening Circle," added Dr. Sharon Hrynkow, Scientific Advisory Board member and Senior Medical Advisor to the company.
On Friday, September 18, CTD Holdings will convene its Family and Physicians Listening Circle under the leadership of Co-Chair Sue French, an advocate for research into NPC cures and treatments. Listening Circle Member Dr. Robin Lachmann, a UK-based physician, will also participate. The Listening Circle is open to all families and caregivers in attendance at the conference. Its goal is to provide a platform for learning and sharing among families, caregivers, CTD Holdings and external scientific experts.
At the September 18 Listening Circle, Professor Frances Platt of the University of Oxford, a leading lysosomal storage disease expert, will discuss where cyclodextrin fits in the proposed treatment options for NPC and some of the unanswered questions about how it mediates its benefit in this disease.
